Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANX005 in Huntington's Disease
NCT04514367Phase 2Completed
- Sponsor
- Annexon Biosciences
- Start
- Sep 2020
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tanruprubart in Huntington's disease (HD), sponsored by Annexon Biosciences. Started Sep 2020; status: completed.
02
Drugs
tanruprubart
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT04514367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04514367.